TEAM-EPIC
Training Network for the Development of Bacterial ExoPolysaccharides for the treatment of Inflammatory Conditions
| Coordinatore | SCHWEIZERISCHES FORSCHUNGSINSTITUT FUER HOCHGEBIRGSKLIMA UND MEDIZIN IN DAVOS
Organization address
address: Promenade 35 contact info |
| Nazionalità Coordinatore | Switzerland [CH] |
| Totale costo | 1˙057˙931 € |
| EC contributo | 1˙057˙931 € |
| Programma | FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013) |
| Code Call | FP7-PEOPLE-2011-IAPP |
| Funding Scheme | MC-IAPP |
| Anno di inizio | 2011 |
| Periodo (anno-mese-giorno) | 2011-12-01 - 2015-11-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
SCHWEIZERISCHES FORSCHUNGSINSTITUT FUER HOCHGEBIRGSKLIMA UND MEDIZIN IN DAVOS
Organization address
address: Promenade 35 contact info |
CH (DAVOS PLATZ) | coordinator | 270˙026.00 |
| 2 |
ALIMENTARY HEALTH LTD
Organization address
address: KINSALE ROAD BUILDING 2800 CORK AIRPORT BUSINESS PARK contact info |
IE ("Passage West, Co. Cork") | participant | 317˙791.00 |
| 3 |
UNIVERSITAET FUER BODENKULTUR WIEN
Organization address
address: Gregor Mendel Strasse 33 contact info |
AT (WIEN) | participant | 207˙192.00 |
| 4 |
ALIMENTARY HEALTH PHARMA DAVOS AG
Organization address
address: OBERE STRASSE 22 contact info |
CH (DAVOS PLATZ) | participant | 141˙863.00 |
| 5 |
UNIVERSITY COLLEGE CORK, NATIONAL UNIVERSITY OF IRELAND, CORK
Organization address
address: Western Road contact info |
IE (CORK) | participant | 121˙059.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The essence of this proposal is to establish a collaborative training network which will develop novel immune-regulatory molecules from Bifidobacterium infantis 35624, for treatment of inflammatory diseases. A multidisciplinary team of four prestigious European partners has been assembled (SME & Coordinator - Alimentary Health Ltd (expert in developing probiotic products); Swiss Institute for Asthma and Allergy Research, (expert in immune-regulation); Vienna Institute of Biotechnology at Universität für Bodenkultur (expert in glycobiology); and University College Cork, Alimentary Pharmabiotics Centre and Department of Microbiology (expert in bioinformatics and glycobiology assembly in probiotic bacteria). Each partner will provide unique critical expertise, through knowledge, personnel and facilities which will be complementary and additive and will provide the synergistic expertise required to successfully deliver on the goal of this project and forge a long-lasting relationship. The end result: a unique opportunity for cross-sector state-of-the-art knowledge transfer and dissemination, through the identification of molecules from B. infantis 35624 with proven efficacy in the treatment of IBS and other inflammatory conditions – expected to have major commercialization, economic and health implications. B. infantis 35624 is a commensal micro-organism, originally isolated from human gastrointestinal tissue, which has demonstrated unique properties in human clinical studies. B. infantis 35624 consumption is associated with significant improvement in the composite score for abdominal pain/discomfort, bloating/distention, and/or bowel movement difficulty compared with placebo in two appropriately designed studies. No other bacterial strain has shown significant improvement in Irritable Bowel Syndrome (IBS) symptoms. The exact mechanisms underpinning the clinical benefit are not known but modulation of the host immune response is strongly believed to play a role.'
Introduzione (Teaser)
As intriguing as it may sound, bacteria could have beneficial effects on our health. With this in mind, a European study is working to develop novel therapies based on bacterial components.